Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Identify and characterise diabetes towards limiting its progression.

Trial Profile

Identify and characterise diabetes towards limiting its progression.

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peptide p277 (Primary)
  • Indications Latent autoimmune diabetes in adults
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTION-LADA

Most Recent Events

  • 06 Mar 2012 Planned end date changed from 1 Sep 2012 to 1 Mar 2012 as reported by UKCRN.
  • 06 Mar 2012 Status changed from recruiting to active, no longer recruiting as reported by UKCRN.
  • 02 Oct 2011 Planned end date changed from 31 Dec 2010 to 1 Sep 2012 as reported by UKCRN.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top